Henning R Stennicke

Summary

Affiliation: Novo Nordisk A/S
Country: Denmark

Publications

  1. ncbi request reprint Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives
    Henning R Stennicke
    Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Thromb Haemost 100:920-8. 2008
  2. pmc A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
    Henning R Stennicke
    Novo Nordisk, Måløv, Denmark
    Blood 121:2108-16. 2013
  3. doi request reprint The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry
    Kasper D Rand
    Department of Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Biol Chem 283:13378-87. 2008
  4. doi request reprint Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa
    Ditte M Karpf
    Novo Nordisk A S, Novo Nordisk Park, Maalov, Denmark
    Thromb Res 128:191-5. 2011
  5. doi request reprint Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma
    Peter B Johansen
    Haemostasis Pharmacology, Biopharmaceuticals Research Unit, Novo Nordisk A S, Måløv, Denmark
    Thromb Haemost 104:157-64. 2010
  6. ncbi request reprint Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study
    Lars C Petersen
    Health Care Discovery, Novo Nordisk A S, Måløv and Bagsvaerd, Denmark
    Thromb Res 116:75-85. 2005
  7. pmc Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa
    Katrine S Larsen
    Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Biochem J 405:429-38. 2007
  8. ncbi request reprint Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange
    Kasper D Rand
    Department of Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Biol Chem 281:23018-24. 2006
  9. doi request reprint Coagulation factor XIII variants with altered thrombin activation rates
    Mette Dahl Andersen
    Biopharmaceutical Research Unit, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Biol Chem 390:1279-83. 2009

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives
    Henning R Stennicke
    Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Thromb Haemost 100:920-8. 2008
    ..However, the modification does to some extend alter the ability of FVIIa to interact with TF and more importantly, reduces the rate of ATIII inhibition by up to 50% which could allow for an extended active half-life in circulation...
  2. pmc A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
    Henning R Stennicke
    Novo Nordisk, Måløv, Denmark
    Blood 121:2108-16. 2013
    ..In conclusion, N8-GP has the potential to offer efficacious prevention and treatment of bleeds in hemophilia A at reduced dosing frequency...
  3. doi request reprint The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry
    Kasper D Rand
    Department of Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Biol Chem 283:13378-87. 2008
    ..These results reveal the delicate interplay between key allosteric sites necessary to achieve the transition of FVIIa into the active form...
  4. doi request reprint Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa
    Ditte M Karpf
    Novo Nordisk A S, Novo Nordisk Park, Maalov, Denmark
    Thromb Res 128:191-5. 2011
    ....
  5. doi request reprint Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma
    Peter B Johansen
    Haemostasis Pharmacology, Biopharmaceuticals Research Unit, Novo Nordisk A S, Måløv, Denmark
    Thromb Haemost 104:157-64. 2010
    ..In perspective, the data support further clinical development of 40k-PEG-rFVIIa to potentially become a long-acting recombinant treatment option for prophylaxis in haemophilia patients with inhibitors...
  6. ncbi request reprint Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study
    Lars C Petersen
    Health Care Discovery, Novo Nordisk A S, Måløv and Bagsvaerd, Denmark
    Thromb Res 116:75-85. 2005
    ..Together, these data confirms the notion of poor species compatibility between human FVII and murine TF and emphasizes the requirement for autologous FVIIa in studies on the role of the TF in experimental in vivo pharmacology...
  7. pmc Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa
    Katrine S Larsen
    Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Biochem J 405:429-38. 2007
    ..Interestingly, these changes do not necessarily coincide with an altered ability to activate Factor X, demonstrating that inhibitor and macromolecular substrate selectivity may be engineered separately...
  8. ncbi request reprint Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange
    Kasper D Rand
    Department of Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Biol Chem 281:23018-24. 2006
    ..The results provide novel insights into the cofactor-induced activation of this important protease and reveal the potential for allosteric regulation in the trypsin family of proteases...
  9. doi request reprint Coagulation factor XIII variants with altered thrombin activation rates
    Mette Dahl Andersen
    Biopharmaceutical Research Unit, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Biol Chem 390:1279-83. 2009
    ..In contrast, introduction of fragments of fibrinopeptide A into the activation peptide resulted in severely impaired activation rates...